Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

1.

Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.

Abdool Karim SS, Abdool Karim Q, Kharsany AB, Baxter C, Grobler AC, Werner L, Kashuba A, Mansoor LE, Samsunder N, Mindel A, Gengiah TN; CAPRISA 004 Trial Group.

N Engl J Med. 2015 Aug 6;373(6):530-9. doi: 10.1056/NEJMoa1410649.

PMID:
26244306
2.

Genital inflammation and the risk of HIV acquisition in women.

Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q, Abdool Karim SS.

Clin Infect Dis. 2015 Jul 15;61(2):260-9. doi: 10.1093/cid/civ298. Epub 2015 Apr 21.

PMID:
25900168
3.

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.

Mansoor LE, Abdool Karim Q, Mngadi KT, Dlamini S, Montague C, Nkomonde N, Mvandaba N, Baxter C, Gengiah TN, Samsunder N, Dawood H, Grobler A, Frohlich JA, Abdool Karim SS.

Trials. 2014 Dec 19;15:496. doi: 10.1186/1745-6215-15-496.

4.

The preventive misconception: experiences from CAPRISA 004.

Dellar RC, Abdool Karim Q, Mansoor LE, Grobler A, Humphries H, Werner L, Ntombela F, Luthuli L, Abdool Karim SS.

AIDS Behav. 2014 Sep;18(9):1746-52. doi: 10.1007/s10461-014-0771-6.

PMID:
24715227
5.

Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Mansoor LE, Abdool Karim Q, Yende-Zuma N, MacQueen KM, Baxter C, Madlala BT, Grobler A, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):811-9. doi: 10.1007/s10461-014-0751-x.

6.

Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study.

Gengiah TN, Upfold M, Naidoo A, Mansoor LE, Feldblum PJ, Abdool Karim Q, Abdool Karim SS.

AIDS Behav. 2014 May;18(5):833-40. doi: 10.1007/s10461-014-0750-y.

7.

Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Mansoor LE, Karim QA, Werner L, Madlala B, Ngcobo N, Cornman DH, Amico KR, Fisher J, Fisher WA, Macqueen KM, Karim SS.

AIDS Behav. 2014 May;18(5):841-8. doi: 10.1007/s10461-014-0752-9.

8.

Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial.

Mngadi KT, Maarschalk S, Grobler AC, Mansoor LE, Frohlich JA, Madlala B, Ngcobo N, Abdool Karim SS, Abdool Karim Q.

AIDS Behav. 2014 May;18(5):849-54. doi: 10.1007/s10461-014-0696-0.

9.

Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial.

Gengiah TN, Mansoor LE, Upfold M, Naidoo A, Yende-Zuma N, Kashuba AD, Karim QA, Karim SS.

AIDS Behav. 2014 May;18(5):820-5. doi: 10.1007/s10461-014-0749-4.

10.

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.

Gengiah TN, Moosa A, Naidoo A, Mansoor LE.

Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Epub 2013 Oct 16. Review.

11.

Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial.

Matthews LT, Sibeko S, Mansoor LE, Yende-Zuma N, Bangsberg DR, Karim QA.

PLoS One. 2013;8(3):e56400. doi: 10.1371/journal.pone.0056400. Epub 2013 Mar 5.

12.

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.

Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A.

AIDS Behav. 2013 Jul;17(6):2143-55. doi: 10.1007/s10461-013-0429-9. Review.

13.

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.

Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.

Antivir Ther. 2013;18(3):301-10. doi: 10.3851/IMP2311. Epub 2012 Aug 23.

PMID:
22914267
14.

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.

Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS.

Expert Opin Investig Drugs. 2012 May;21(5):695-715. doi: 10.1517/13543784.2012.667072. Epub 2012 Mar 7. Review.

15.

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.

Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.

Trials. 2011 Mar 7;12:67. doi: 10.1186/1745-6215-12-67.

16.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

17.

Medicines information and adherence in HIV/AIDS patients.

Mansoor LE, Dowse R.

J Clin Pharm Ther. 2006 Feb;31(1):7-15.

PMID:
16476115
18.

Effect of pictograms on readability of patient information materials.

Mansoor LE, Dowse R.

Ann Pharmacother. 2003 Jul-Aug;37(7-8):1003-9.

PMID:
12841808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk